替格瑞洛的champion phoenix iii期临床试验结果.ppt

CHAMPION PHOENIX
Deepak L. Bhatt, MD, MPH, Gregg W. Stone, MD, h W. Mahaffey, MD, C. Michael Gibson, MS, MD, Ph. Gabriel Steg, MD, Christian Hamm, MD, Matthew Price, MD, Sergio Leonardi, MD, Dianne Gallup, MS, Meredith Todd, Simona Skerjanec, PharmD, Harvey D. White, DSc, and Robert A. Harrington, MD, on behalf of the CHAMPION PHOENIX Investigators
Dr. Bhatt – Advisory Board: Medscape Cardiology; Board of Directors: Boston VA Research Institute, Society of Chest Pain Centers; Chair: American Heart Association Get With The Guidelines Science mittee; Honoraria: American College of Cardiology (Editor, Clinical Trials, Cardiosource), Duke Clinical Research Institute (clinical trial mittees), Slack Publications (Chief Medical Editor, Cardiology Today Intervention), WebMD (CME mittees); Other: Senior Associate Editor, Journal of Invasive Cardiology; Research Grants: Amarin, AstraZeneca, Bristol-Myers Squibb, Eisai, Ethicon, Medtronic, Sanofi Aventis, The pany; Unfunded Research: FlowCo, PLx Pharma, Takeda.
This presentation includes off-label and/or investigational uses of drugs, including clopidogrel and cangrelor.
The CHAMPION PHOENIX trial was funded by The pany.
Disclosures
Antiplatelet Therapy
Antiplatelet therapy is a critical part of contemporary PCI.
In the era of aspirin and unfractionated heparin, intravenous glycoprotein IIb/IIIa inhibition significantly reduced important periprocedural ischemic events, but significantly increased bleeding.
ADP receptor antagonism with oral agents was also shown to reduce ischemic events in PCI and especially ACS.
However, available oral agents are limited by their relatively long duration of action and bioavailability, which might be a liability:
if given prior to coronary angiography and urgent or emergent CABG is deemed necessary,
in situations where absorption may be problematic, such as with rapid times to PCI,
in patients who are intubated, nauseated, with STEMI, or shock.
Harrington RA, et al. PURSUIT. NEJM 19